MedTrace Logo

Biomarkers in Blood Samples From Patients With Stage IV Melanoma Previously Treated With Sargramostim

NCT01388569 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2017-05-17

No results posted yet for this study

Summary

RATIONALE: Studying samples of blood from patients treated with sargramostim in the laboratory may help doctors learn more about the effects of sargramostim on cells. It may also help doctors understand how patients respond to treatment.

PURPOSE: This research trial studies biomarkers in blood samples from patients with stage IV melanoma previously treated with sargramostim.

Conditions

  • Melanoma (Skin)

Interventions

OTHER

flow cytometry

OTHER

immunologic technique

OTHER

laboratory biomarker analysis

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Eastern Cooperative Oncology Group

    lead NETWORK

Principal Investigators

  • Lisa Butterfield, PhD · University of Pittsburgh

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-28
Primary Completion
2011-09-28
Completion
2011-09-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01388569 on ClinicalTrials.gov